Precision medicine ethics

Selected issues and developments in next-generation sequencing, clinical oncology, and ethics

Robin N. Fiore, Kenneth Goodman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In early 2015 the National Institutes of Health launched a new, national Precision Medicine Initiative with the primary goal of rapidly improving the prevention, diagnosis, and treatment of cancers. The first-stage emphasis on oncology presents unique opportunities for clinical oncology to influence how the ethical challenges of precision medicine are to be articulated and addressed. Thus, a review of recent developments in connection with the Initiative, in particular on core ethics issues in clinical genomics, is a useful starting point. Recent findings Unique ethical issues arise in precision medicine because of the enormous amounts of data generated by clinical whole-genome or whole-exome sequencing and the extent of current uncertainties with respect to data interpretations and disease associations. Among the most ethically challenging issues for clinicians are complicated informed consent processes, returning results-particularly secondary and incidental findings-and privacy and confidentiality. Summary The first tests of precision medicine ethics in practice will be in clinical oncology, providing a rare opportunity to shape the agenda and integrate practical ethics considerations. These efforts can benefit from pre-existing research ethics analyses and recommendations from clinical and translational genetics research.

Original languageEnglish (US)
Pages (from-to)83-87
Number of pages5
JournalCurrent Opinion in Oncology
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Clinical Ethics
Precision Medicine
Medical Oncology
Ethics
Exome
Research Ethics
Genetic Research
Incidental Findings
Translational Medical Research
Privacy
Confidentiality
National Institutes of Health (U.S.)
Genomics
Informed Consent
Uncertainty
Genome
Neoplasms

Keywords

  • Ethics
  • next-generation sequencing
  • precision medicine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Precision medicine ethics : Selected issues and developments in next-generation sequencing, clinical oncology, and ethics. / Fiore, Robin N.; Goodman, Kenneth.

In: Current Opinion in Oncology, Vol. 28, No. 1, 01.01.2016, p. 83-87.

Research output: Contribution to journalArticle

@article{bb9ea0c34d2f4b3eae29c0ba88b0fcc9,
title = "Precision medicine ethics: Selected issues and developments in next-generation sequencing, clinical oncology, and ethics",
abstract = "In early 2015 the National Institutes of Health launched a new, national Precision Medicine Initiative with the primary goal of rapidly improving the prevention, diagnosis, and treatment of cancers. The first-stage emphasis on oncology presents unique opportunities for clinical oncology to influence how the ethical challenges of precision medicine are to be articulated and addressed. Thus, a review of recent developments in connection with the Initiative, in particular on core ethics issues in clinical genomics, is a useful starting point. Recent findings Unique ethical issues arise in precision medicine because of the enormous amounts of data generated by clinical whole-genome or whole-exome sequencing and the extent of current uncertainties with respect to data interpretations and disease associations. Among the most ethically challenging issues for clinicians are complicated informed consent processes, returning results-particularly secondary and incidental findings-and privacy and confidentiality. Summary The first tests of precision medicine ethics in practice will be in clinical oncology, providing a rare opportunity to shape the agenda and integrate practical ethics considerations. These efforts can benefit from pre-existing research ethics analyses and recommendations from clinical and translational genetics research.",
keywords = "Ethics, next-generation sequencing, precision medicine",
author = "Fiore, {Robin N.} and Kenneth Goodman",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/CCO.0000000000000247",
language = "English (US)",
volume = "28",
pages = "83--87",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Precision medicine ethics

T2 - Selected issues and developments in next-generation sequencing, clinical oncology, and ethics

AU - Fiore, Robin N.

AU - Goodman, Kenneth

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In early 2015 the National Institutes of Health launched a new, national Precision Medicine Initiative with the primary goal of rapidly improving the prevention, diagnosis, and treatment of cancers. The first-stage emphasis on oncology presents unique opportunities for clinical oncology to influence how the ethical challenges of precision medicine are to be articulated and addressed. Thus, a review of recent developments in connection with the Initiative, in particular on core ethics issues in clinical genomics, is a useful starting point. Recent findings Unique ethical issues arise in precision medicine because of the enormous amounts of data generated by clinical whole-genome or whole-exome sequencing and the extent of current uncertainties with respect to data interpretations and disease associations. Among the most ethically challenging issues for clinicians are complicated informed consent processes, returning results-particularly secondary and incidental findings-and privacy and confidentiality. Summary The first tests of precision medicine ethics in practice will be in clinical oncology, providing a rare opportunity to shape the agenda and integrate practical ethics considerations. These efforts can benefit from pre-existing research ethics analyses and recommendations from clinical and translational genetics research.

AB - In early 2015 the National Institutes of Health launched a new, national Precision Medicine Initiative with the primary goal of rapidly improving the prevention, diagnosis, and treatment of cancers. The first-stage emphasis on oncology presents unique opportunities for clinical oncology to influence how the ethical challenges of precision medicine are to be articulated and addressed. Thus, a review of recent developments in connection with the Initiative, in particular on core ethics issues in clinical genomics, is a useful starting point. Recent findings Unique ethical issues arise in precision medicine because of the enormous amounts of data generated by clinical whole-genome or whole-exome sequencing and the extent of current uncertainties with respect to data interpretations and disease associations. Among the most ethically challenging issues for clinicians are complicated informed consent processes, returning results-particularly secondary and incidental findings-and privacy and confidentiality. Summary The first tests of precision medicine ethics in practice will be in clinical oncology, providing a rare opportunity to shape the agenda and integrate practical ethics considerations. These efforts can benefit from pre-existing research ethics analyses and recommendations from clinical and translational genetics research.

KW - Ethics

KW - next-generation sequencing

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=84951570610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951570610&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000247

DO - 10.1097/CCO.0000000000000247

M3 - Article

VL - 28

SP - 83

EP - 87

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 1

ER -